Figure 1.

The genotyping study population. In top level boxes, N is the number of patients who received study drug, including 40 given valganciclovir in trial 203. Numbers in lower level boxes are the count of patients with available genotypic data at baseline (all patients) or with different outcomes after maribavir (MBV) therapy. Nonresponder group received maribavir for >14 days. Viral DNA sequencing was performed at the central laboratory (C), supplemented by local laboratory testing (L) at baseline. Baseline genotypic data included portions of genes UL27, UL54, and UL97, and posttreatment data included UL27 and UL97. Not all patients had coverage of all targeted genes.